Back to Results

A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients with Solid Tumors

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

enrolling to Expansion cohorts only: SCCL, HNSCC, HR+ breast cancer, and PARP7 amplified cancer.

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Erin Schenk,  MD, PhD

Erin Schenk, MD, PhD

Study ID

Protocol Number: 21-3286

More information available at ClinicalTrials.gov: NCT04053673

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers